脑胶质瘤患者继发第二原发恶性肿瘤的相关分析

doi:10.19854/j.cnki.1008-2425.2024.04.0002

立体定向和功能性神经外科杂志 ›› 2024, Vol. 37 ›› Issue (4): 199-204.DOI: 10.19854/j.cnki.1008-2425.2024.04.0002

脑胶质瘤患者继发第二原发恶性肿瘤的相关分析

牛万祥, 慕茂林, 张宏伟, 计颖, 程传东

230001 中国科学技术大学附属第一医院(安徽省立医院)神经外科(牛万祥, 慕茂林, 张宏伟, 计颖, 程传东), 脑功能与脑疾病安徽省重点实验室(牛万祥, 慕茂林, 张宏伟, 程传东), 安徽理工大学(张宏伟, 程传东)

收稿日期:2024-08-13 出版日期:2024-08-25 发布日期:2024-11-12
通讯作者: 程传东 doctorcd@ustc.edu.cn
基金资助:
国家自然科学基金项目(编号:62376256),安徽省临床医学研究转化专项(编号:202204295107020020),医学人工智能联合基金(编号:MAI2022Q011)

Correlation analysis of second primary malignancies in patients with glioma

Niu Wanxiang^1,2, Mu Maolin^1,2, Zhang Hongwei^1,2,3, Ji Ying¹, Cheng Chuandong^1,2,3

1. Department of Neurosurgery, The First Affiliated Hospital of USTC, Hefei, Anhui, 230001, China;
2. Anhui Key Laboratory of Brain Function and Diseases, Hefei, Anhui, 230036, China;
3. Anhui University of Science and Technology, Huainan, Anhui, 232001, China

Received:2024-08-13 Online:2024-08-25 Published:2024-11-12
Contact: Cheng Chuandong doctorcd@ustc.edu.cn

摘要/Abstract

摘要： 目的分析脑胶质瘤患者继发第二原发恶性肿瘤(second primary malignancy,SPM)的发生情况及其危险因素。方法收集2000年1月至2021年12月监测、流行病学和结果(surveillance,epidemiology,and end results,SEER)数据库中诊断为脑胶质瘤患者的病例资料,回顾性分析患者的人口学特征、临床特征与SPM发生情况,采用单因素、多因素Cox风险回归分析其危险因素。结果从SEER数据库中共筛选出87889例脑胶质瘤患者,其中发生SPM患者为1043例。发生SPM患者中位总生存时间(overall survival,OS)为105.0个月。主要部位为乳腺(34.08%),肺和支气管(11.27%)以及甲状腺(10.99%)。多因素Cox回归显示,年龄(≥65岁:HR=3.047,95%CI:2.570~3.613,P＜0.001)、病理(胶质母细胞瘤:HR=2.091,95%CI:1.7930~2.438,P＜0.001)和放疗(HR=1.489,95%CI:1.276~1.736,P＜0.001)是影响SPM发生的独立危险因素。结论乳腺、肺和支气管和甲状腺是脑胶质瘤患者SPM最常见的发生部位,年龄、病理和放疗是SPM发生的重要危险因素,这些危险因素的确定能够指导脑脑胶质瘤患者的个性化随访及SPM的筛查。

关键词: 脑胶质瘤, 第二原发肿瘤, SEER数据库, 危险因素

Abstract: Objective To analyze the occurrence of second primary malignancies (SPM) in patients with glioma and identify their risk factors. Methods Cases of glioma patients diagnosed from January 2000 to December 2021 were collected from the Surveillance,Epidemiology,and End Results (SEER) database.A retrospective analysis was performed on patients' demographic characteristics,clinical features,and SPM occurrence,using univariate and multivariate Cox regression analysis to identify risk factors. Results A total of 87,889 glioma patients were screened from the SEER database,with 1,043 developing SPM.The median overall survival (OS) for patients with SPM was 105.0 months.The most common sites for SPMs were the breast (34.08%),lung and bronchi (11.27%),and thyroid (10.99%).Multivariate Cox regression analysis showed that age (≥65 years:HR=3.047,95% CI:2.570~3.613,P＜0.001),pathology (glioblastoma:HR=2.091,95% CI:1.793~2.438,P＜0.001),and radiotherapy (HR=1.489,95% CI:1.276~1.736,P＜0.001) were independent risk factors for the occurrence of SPM. Conclusion Breast,lung and bronchi,and thyroid are the most common sites of SPM in glioma patients.Age,pathology,and radiotherapy are significant risk factors for SPM occurrence.Identifying these risk factors can guide personalized follow-up and screening for SPM in glioma patients.

Key words: Glioma, Second primary malignancy, SEER database, Risk factors

中图分类号:

R739.41

牛万祥, 慕茂林, 张宏伟, 计颖, 程传东. 脑胶质瘤患者继发第二原发恶性肿瘤的相关分析[J]. 立体定向和功能性神经外科杂志, 2024, 37(4): 199-204.

Niu Wanxiang, Mu Maolin, Zhang Hongwei, Ji Ying, Cheng Chuandong. Correlation analysis of second primary malignancies in patients with glioma[J]. Chinese Journal of Stereotactic and Functional Neurosurgery, 2024, 37(4): 199-204.

参考文献

[1] Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209~249.
[2] Cao W,Chen HD,Yu YW,et al.Changing profiles of cancer burden worldwide and in China:a secondary analysis of the global cancer statistics 2020[J].Chin Med J (Engl),2021,134(7):783~791.
[3] Ohgaki H,Kleihues P.Population-based studies on incidence,survival rates,and genetic alterations in astrocytic and oligodendroglial gliomas[J].J Neuropathol Exp Neurol,2005,64(6):479~489.
[4] Bleeker FE,Molenaar RJ,Leenstra S.Recent advances in the molecular understanding of glioblastoma[J].J Neurooncol,2012,108(1):11~27.
[5] Sadowski K,Jaždžewska A,Kozłowski J,et al.Revolutionizing glioblastoma treatment:A comprehensive overview of modern therapeutic approaches[J].Int J Mol Sci,2024,25(11):5774.
[6] Warren S .Multiple primary malignant tumors:a survey of the literature and a statistical study[J].Gastroenterology,1932,93(4):779.
[7] Siegel RL,Miller KD,Jemal A.Cancer statistics,2017[J].CA Cancer J Clin,2017,67(1):7~30.
[8] Li X,Li Y,Cao Y,et al.Risk of subsequent cancer among pediatric,adult and elderly patients following a primary diagnosis of glioblastoma multiforme:a population-based study of the SEER database[J].Int J Neurosci,2017,127(11):1005~1011.
[9] Wang W.Increased incidence of second primary malignancy in patients with malignant astrocytoma:a population-based study[J].Biosci Rep,2019,39(6):BSR20181968.
[10] Jia H,Li Q,Yuan J,Sun X,Wu Z.Second primary malignancies in patients with colorectal cancer:A population-based analysis[J].Oncologist,2020,25(4):e644~e650.
[11] 李晓多,杨峤,张春高,等.原发性腹膜癌继发第二原发恶性肿瘤的相关分析[J].重庆医学,2022,51(6):995~999.
[12] Han W,Wang S,Su L,et al.Prognostic analysis of lung squamous cell carcinoma patients with second primary malignancies:a SEER database study[J].Front Oncol,2024,14:1294383.
[13] Aldape K,Zadeh G,Mansouri S,et al.Glioblastoma:pathology,molecular mechanisms and markers[J].Acta Neuropathol,2015,129(6):829~848.
[14] Li X,Zhao L,Chen C,et al.Can EGFR be a therapeutic target in breast cancer[J] ?Biochim Biophys Acta Rev Cancer,2022,1877(5):188789.
[15] Passaro A,Jänne PA,Mok T,et al.Overcoming therapy resistance in EGFR-mutant lung cancer[J].Nat Cancer,2021,2(4):377~391.
[16] Abe I,Lam AK.Anaplastic thyroid carcinoma:current issues in genomics and therapeutics[J].Curr Oncol Rep,2021,23(3):31.
[17] Hiddinga BI,Pauwels P,Janssens A,et al.O6-Methylguanine-DNA methyltransferase (MGMT):A drugable target in lung cancer[J].Lung Cancer,2017,107:91~99.
[18] Müller D,Györffy B.DNA methylation-based diagnostic,prognostic,and predictive biomarkers in colorectal cancer[J].Biochim Biophys Acta Rev Cancer,2022,1877(3):188722.
[19] Bai P,Fan T,Sun G,et al.The dual role of DNA repair protein MGMT in cancer prevention and treatment[J].DNA Repair (Amst),2023,123:103449.
[20] Wu M,Huang M,He C,et al.Risk of second primary malignancies based on the histological subtypes of colorectal cancer[J].Front Oncol,2021,11:650937.
[21] Chen M,Pan X,Wang H,et al.The risk and latency evaluation of secondary primary malignancies of cervical cancer patients who received radiotherapy:A study based on the SEER database[J].Front Oncol,2023,12:1054436.
[22] Huang H,Li Z,Huang Z,et al.Development and validation of nomograms to predict the survival probability and occurrence of a second primary malignancy of male breast cancer patients:a population-based analysis[J].Front Oncol,2023,13:1076997.
[23] Li J,Peng F,Huang H,et al.Trends in the risk of second primary malignances after non-Hodgkin's lymphoma[J].Am J Cancer Res,2022,12(6):2863~2875.
[24] Huang K,Xu L,Jia M,et al.Second primary malignancies in cervical cancer and endometrial cancer survivors:a population-based analysis[J].Aging (Albany NY),2022,14(9):3836~3855.

脑胶质瘤患者继发第二原发恶性肿瘤的相关分析

Correlation analysis of second primary malignancies in patients with glioma

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	彭超, 陈宇澄, 张之娟, 廖黎庆. 脑胶质瘤患者SEL1L基因多态性与总生存率和替莫唑胺敏感性的关系[J]. 立体定向和功能性神经外科杂志, 2024, 37(4): 205-209.
[2]	徐峰, 程毛锋. 高血压脑出血患者术后并发脑梗死的危险因素分析[J]. 立体定向和功能性神经外科杂志, 2024, 37(4): 222-226.
[3]	魏曙岚, 陈炜钰, 花胜松. 个体化预测重型颅脑损伤患者术后并发脑积水的风险列线图模型的建立[J]. 立体定向和功能性神经外科杂志, 2024, 37(3): 165-170.
[4]	王国杰, 刘莹, 韩艳华, 任秀娥, 梁日晶. 胶质瘤患者MRI参数Ktrans值和Ve值与血清IL-10、VEGF的交互作用及对脑胶质瘤分级的诊断[J]. 立体定向和功能性神经外科杂志, 2024, 37(1): 11-16.
[5]	刘梦, 杜云, 刘佳, 姚萌萌, 王卫中. IDH1与高级别脑胶质瘤治疗后MRI特征及预后分析[J]. 立体定向和功能性神经外科杂志, 2023, 36(5): 262-268.
[6]	杜云, 王卫中, 刘梦, 姚萌萌. 异柠檬酸脱氢酶1R132H与同源框C10在脑胶质瘤组织的表达及其临床意义[J]. 立体定向和功能性神经外科杂志, 2023, 36(3): 135-140.
[7]	蒋友田, 王云龙, 袁文浩, 张小飞, 刘金龙. 颅内动脉瘤栓塞术后再出血原因分析[J]. 立体定向和功能性神经外科杂志, 2023, 36(3): 178-181.
[8]	孟少林, 王伟, 孟凡然, 冯会玉, 何晨曦, 徐伟, 高飞. 基于多模态核磁共振成像脑胶质瘤术后调强适形放疗对患者自主神经反应的影响[J]. 立体定向和功能性神经外科杂志, 2023, 36(1): 22-28.
[9]	刘美霞, 周龙, 田仁富, 潘轲, 向春晖. 脑胶质瘤患者立体定向切除术前后认知功能变化及β-EP、3-NT预测认知功能障碍价值探讨[J]. 立体定向和功能性神经外科杂志, 2023, 36(1): 29-34.
[10]	陈锋龙, 陈金龙, 张弋. 75岁以上人群破裂颅内动脉瘤栓塞术后早期预后相关因素分析[J]. 立体定向和功能性神经外科杂志, 2022, 35(6): 321-325.
[11]	李政, 奚之玉, 鲍得俊, 牛朝诗. 术前梗死脑组织/全脑体积比值与脑梗死患者去骨瓣减压术后预后的关系[J]. 立体定向和功能性神经外科杂志, 2022, 35(6): 343-349.
[12]	杜云, 王卫中, 刘梦, 姚萌萌. Notch3与TIP30表达对脑胶质瘤患者预后评估价值[J]. 立体定向和功能性神经外科杂志, 2022, 35(5): 273-279.
[13]	陈欢, 郝璐, 王禄伟, 马景旭, 刘莹, 姜磊, 王红. 磁共振灌注加权成像联合NODDI技术对脑胶质瘤分级诊断的临床价值分析[J]. 立体定向和功能性神经外科杂志, 2022, 35(3): 142-146.
[14]	关沛, 曹娅妮. 基于ERAS的术中唤醒麻醉技术对脑胶质瘤患者肿瘤切除程度、术后语言及运动功能的影响[J]. 立体定向和功能性神经外科杂志, 2022, 35(3): 147-152.
[15]	侯现春, 王鸿, 常彦杰, 吴升华, 张建磊, 孙传波. ICU自发性脑出血后癫痫发作及预防性抗癫痫发作药物应用价值的临床研究[J]. 立体定向和功能性神经外科杂志, 2022, 35(3): 153-159.